Thursday, March 19, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Virtual care regresses to pre-pandemic levels

The COVID-19 pandemic forced most U.S. healthcare systems to quickly pivot to virtual care. However, since peaking in late April, care has largely shifted back to in-person. Health systems are now challenged to further develop and integrate useful, usable, and sustainable virtual care tools into their broader care model in ways that benefit their organizations and the communities they serve.

At the start of 2020, very few U.S. healthcare systems had embraced virtual care at scale1. Incentives to use these tools were generally not strong enough to overcome considerable barriers to change. By March, in the face of the COVID-19 pandemic, most systems quickly pivoted to virtual care to preserve care access, protect their patients, sustain their workforces, and maintain revenue. Within weeks, most systems were providing more virtual care—including video and phone visits, eVisits, eConsults, and messaging with clinicians and chatbots—in a single day than they had the entire prior year.

However, since peaking in late April 2020, care has largely shifted back from virtual to in-person2,3, sometimes because in-person care is more clinically appropriate, but often simply because it is more familiar, more accessible, and easier to provide. Healthcare systems are now at a crossroads. Some will continue to build on their virtual care platforms to benefit their patients and advance their organizational goals. Others will backslide to business as usual, sacrificing their recently hard-earned gains and jeopardizing their long-term positions.

Source: Nature

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!